Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Every story we pull is tagged to the disease it’s about — so you can filter to your condition and read only what matters.
Showing news related to
active surveillance for intermediate risk prostate cancer the manitoba prostate center experience
Original title: “Active surveillance for intermediate risk prostate cancer: the Manitoba Prostate Center experience.”
mismatch repair deficiency and programmed death ligand 1 expression in treatment na ve high risk and very high risk locally advanced prostate cancer histomorphological associations and prognostic value
Original title: “Mismatch Repair Deficiency and Programmed Death-Ligand 1 Expression in Treatment-Naïve High-Risk and Very High-Risk Locally Advanced Prostate Cancer: Histomorphological Associations and Prognostic Value.”
transcriptional profiling of circulating extracellular vesicles from prebiopsy prostate cancer patients
Original title: “Transcriptional profiling of circulating extracellular vesicles from prebiopsy prostate cancer patients.”
While sales of Talzenna, which Pfizer acquired in a $14 billion deal, have been “negligible” so far, the new results should justify use in earlier lines of care, one analyst said.
Original title: “Pfizer aims for wider use of PARP drug in prostate cancer with new data”
The FDA's cancer advisors will discuss AstraZeneca’s application for the oral SERD camizestrant in breast cancer and the AKT inhibitor Truqap in prostate cancer.
Original title: “Two AstraZeneca Drugs To Be Scrutinized in First FDA Cancer Advisory Panel in 9 Months”
In a Phase 1 study, 82% of patients on VIR-5500 achieved at least a 50% reduction in PSA levels—a result analysts praised as competitive in the prostate cancer space.
Original title: “Astellas Bets up to $1.7B for Vir’s ‘Robust Competitor’ in Prostate Cancer”
cancer specific mortality in rare histological subtypes of prostate cancer radical prostatectomy versus radiation therapy
Original title: “Cancer-Specific Mortality in Rare Histological Subtypes of Prostate Cancer: Radical Prostatectomy Versus Radiation Therapy.”
metastatic castrate resistant prostate cancer to the penis resulting in malignant priapism and urethral obstruction
Original title: “Metastatic castrate-resistant prostate cancer to the penis resulting in malignant priapism and urethral obstruction.”
genetic diagnosis of macrotia in pik3ca related overgrowth spectrum pros and long term outcome of otoplasty a case report and literature review
Original title: “Genetic diagnosis of macrotia in PIK3CA-Related Overgrowth Spectrum (PROS) and long-term outcome of otoplasty: a case report and literature review.”
Prostate Cancer and Prostatic Diseases - Editorial: Advancing external beam radiotherapy—and rediscovering what brachytherapy already provides? Prostate Cancer and Prostatic Diseases (2026)Cite this article ... We read with interest the article entitled “Reducing adverse effects in hypofractionated radiotherapy for prostate cancer: Clinical evidence and emerging mitigation strategies,” and commend the authors for their comprehensive synthesis of toxicity data in this evolving field. In this systematic review, evidence from 32 phase III clinical trials was analyzed and summarized. Furthermore, other randomized trials have failed to demonstrate an excess in toxicity compared with EBRT alone [3, 4], or to report clinically meaningful levels of severe toxicity [6] comparable to those observed in ASCENDE-RT [5]. Certainly, not all patients are candidates for prostate brachytherapy or should undergo boost treatment with this modality. Finally, the utilization of brachytherapy as a boost has been demonstrated to reduce biochemical disease progression and local relapse when compared to augmented radiotherapy schedules [3,4,5], a feature just recently achieved by external beam alone, through focal boosting to the dominant lesions as nicely demonstrated in the FLAME-trial [NCT01168479]. Toxicity associated with prostate brachytherapy has been raised as a concern, leading some to forgo this treatment strategy in favor of external beam radiotherapy (EBRT) alone. In this context, we highlight the efforts of the PR24 trial for directly comparing brachytherapy boost versus SBRT in a large international phase III study [NCT06235697]. Le Guevelou J, Zilli T, Ferrario F, Murthy V, Tree A, Loblaw A, et al. Reducing adverse effects in hypofractionated radiotherapy for prostate cancer: clinical evidence and emerging mitigation strategies.
Original title: “Editorial: Advancing external beam radiotherapy—and rediscovering what brachytherapy already provides? | Prostate Cancer and Prostatic Diseases”